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Systemic sclerosis (SSc) is a complex inflammatory connective tissue disease characterized by skin thickening, organ fibrosis and vasculopathy [1, 2] . The underlying disease mechanisms and pathophysiology are not fully understood. However, it appears to be, at least in part, driven by autoimmunity and inflammation associated with microvascular dysfunction ultimately resulting in excess extracellular matrix deposition in target organs [2] [3] [4] . Clinical heterogeneity coupled with our lack of understanding of the disease pathogenesis means that current treatment strategies are mostly organ based therapies using anti-rheumatic drugs that were originally approved for other indications [5] . Of course, this clinical diversity not only provides challenges to discovery of disease mechanisms, it also complicates often underpowered clinical trials that aim to find the right drugs for the right patient at the right time.
One approach towards discovery of the "Goldilocks Zone" of disease modifying therapy for all patients with SSc is starting at a point of known commonality. For example, SSc is often characterized by the presence of autoantibodies [6, 7] . More specifically, there have been recent interest in B-cell biology and modulation, including data derived from animal models of disease, human tissue analyses and even small randomized clinical trials of B-cell depletion in patients with SSc [6, 8, 9] . In addition to their role in autoantibody formation, B-cells have been shown to be elevated in blood and tissue samples of patients with SSc, with abnormal chronic activation while demonstrating secretion of important disease cytokines such as IL-6 and TGF-β [6] . 
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This co-therapy makes it impossible to attribute any treatment effect solely to belimumab and may have blunted the difference in treatment response between the two groups. However, it allowed for all patients to receive standard of care which enhances recruitment and allows for good clinical practice. Future studies may need to determine if MMF is needed and also if other immune suppressive drugs could be used. This study provides data for a power calculation of a larger trial.
The gene expression analysis may be difficult to interpret due to small numbers and there may be the MMF response and natural history confounding the belimumab effect.
However, they showed modulation of B cell receptor activation and pro-fibrotic signaling in the belimumab arm and not in clinical improvers in the placebo group.
In conclusion, novel early-stage trial designs that incorporate standard of care treatment and biomarkers to understand response such as gene expression within a randomized trial may be considered a template for future SSc trials.
